March 3, 2020 / 1:08 PM / 25 days ago

BRIEF-VBI Vaccines Provides Update On Part A Of Ongoing Phase 1/2A Study Demonstrating Overall Survival Benefit For VBI-1901 Vaccine Responders In Recurrent GBM Patients

March 3 (Reuters) - VBI Vaccines Inc:

* VBI VACCINES PROVIDES UPDATE ON PART A OF ONGOING PHASE 1/2A STUDY DEMONSTRATING OVERALL SURVIVAL BENEFIT FOR VBI-1901 VACCINE RESPONDERS IN RECURRENT GBM PATIENTS

* VBI VACCINES INC - VBI-1901 CONTINUES TO BE SAFE AND WELL-TOLERATED, WITH NO VACCINE-RELATED SAFETY SIGNALS OBSERVED

* VBI VACCINES INC - VACCINE RESPONDERS SAW A 6.25-MONTH IMPROVEMENT IN MEDIAN OS COMPARED TO NON-RESPONDERS

* VBI VACCINES INC - EXPANDED IMMUNOLOGIC, TUMOR IMAGING, AND CLINICAL DATA FROM PHASE 2A PART OF STUDY ARE EXPECTED IN Q2 2020 AND Q4 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below